YI-HSIN LIANGKUO-HSING CHENYU-YUN SHAO2023-07-142023-07-142023-06-162045-7634https://scholars.lib.ntu.edu.tw/handle/123456789/633599The first-line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) is the more effective addition to a chemotherapy doublet as the first-line treatment for inoperable KRAS wild-type mCRC remains controversial in prior clinical trials. Moreover, the association between the sidedness of primary tumors and the efficacy of anti-EGFR mAb needs to be addressed.enEGFR; bevacizumab; cetuximab; metastatic colorectal cancer; panitumumab; secondary surgery[SDGs]SDG3journal article10.1002/cam4.6196373259702-s2.0-85162012990https://api.elsevier.com/content/abstract/scopus_id/85162012990